Cargando…

Evaluation of a Self-Administered Oral Glucose Tolerance Test

OBJECTIVE: To assess the feasibility of using a disposable, self-administered, capillary blood sampling oral glucose tolerance test (OGTT) device in a community setting. RESEARCH DESIGN AND METHODS: Eighteen healthy and 12 type 2 diabetic volunteers underwent six 75-g OGTTs using a prototype device...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bethel, M. Angelyn, Price, Hermione C., Sourij, Harald, White, Sarah, Coleman, Ruth L., Ring, Arne, Kennedy, Irene E.C., Tucker, Lynne, Holman, Rury R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661807/ https://www.ncbi.nlm.nih.gov/pubmed/23321216 http://dx.doi.org/10.2337/dc12-0643

Ejemplares similares

The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial
por: Price, Hermione C, et al.
Publicado: (2008)

Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes
por: Coleman, Ruth L., et al.
Publicado: (2019)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
por: Bethel, M. Angelyn, et al.
Publicado: (2023)

Progression of glucose‐lowering diabetes therapy in TECOS
por: Bethel, M. Angelyn, et al.
Publicado: (2018)

Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort
por: Simmons, Rebecca K., et al.
Publicado: (2009)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study
por: Shen, Lan, et al.
Publicado: (2013)

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial
por: Kraus, William E, et al.
Publicado: (2018)

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL
por: Idzerda, Nienke M. A., et al.
Publicado: (2020)

Pre-Exercise Blood Glucose Levels Determine the Amount of Orally Administered Carbohydrates during Physical Exercise in Individuals with Type 1 Diabetes—A Randomized Cross-Over Trial
por: Moser, Othmar, et al.
Publicado: (2019)

Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double‐blind, placebo‐controlled trial
por: Leal, José, et al.
Publicado: (2022)

Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice
por: Niedowicz, Dana M., et al.
Publicado: (2018)

Health selection into neighborhoods among patients enrolled in a clinical trial
por: Arcaya, Mariana C., et al.
Publicado: (2017)

Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on post‐meal glucose excursions and glucagon in type 1 diabetes patients
por: Ballav, Chitrabhanu, et al.
Publicado: (2020)

Historical HbA(1c) Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88
por: Lind, Marcus, et al.
Publicado: (2021)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
por: Preiss, David, et al.
Publicado: (2012)

International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial
por: Harumi Higuchi dos Santos, Marilia, et al.
Publicado: (2017)

The effect of a brief action planning intervention on adherence to double-blind study medication compared to a standard trial protocol in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study
por: Farmer, Andrew J., et al.
Publicado: (2016)

Performance of the Intermittently Scanned Continuous Glucose Monitoring (isCGM) System during a High Oral Glucose Challenge in Adults with Type 1 Diabetes—A Prospective Secondary Outcome Analysis
por: Moser, Othmar, et al.
Publicado: (2021)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Effect of orally administered dipterinyl calcium pentahydrate on oral glucose tolerance in diet-induced obese mice
por: Nikoulina, Svetlana E, et al.
Publicado: (2012)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

Self-administered oral glucose tolerance test with capillary glucose measurements for the screening of diabetes mellitus in high-risk adults: a feasibility study
por: Tan, Andrew Yen Siong, et al.
Publicado: (2021)

HbA(1c) Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression
por: Bethel, M. Angelyn, et al.
Publicado: (2021)

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease
por: LeWitt, Peter A., et al.
Publicado: (2018)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates
por: Jain, Meena, et al.
Publicado: (2017)

Comparative Analysis of Predictive Interstitial Glucose Level Classification Models
por: Kistkins, Svjatoslavs, et al.
Publicado: (2023)

Rapid glucose rise reduces heart rate variability in adults with type 1 diabetes: A prospective secondary outcome analysis
por: Eckstein, Max L., et al.
Publicado: (2021)

Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid
por: Price, Hermione C, et al.
Publicado: (2009)

Timing of SGLT2i initiation after acute myocardial infarction
por: von Lewinski, Dirk, et al.
Publicado: (2023)

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine
por: Riede, O, et al.
Publicado: (2015)

Effect of Once‐Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial
por: Mentz, Robert J., et al.
Publicado: (2018)

Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective
por: Aberer, Felix, et al.
Publicado: (2022)

Prediction of Glucose Tolerance without an Oral Glucose Tolerance Test
por: Babbar, Rohit, et al.
Publicado: (2018)

Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1‐1Δ
por: Heit, Mark C., et al.
Publicado: (2021)

Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study
por: Xu, Shishi, et al.
Publicado: (2022)

Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance
por: Schmoelzer, Isabella, et al.
Publicado: (2006)

Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals
por: Melanson, Stacy E. F., et al.
Publicado: (2022)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2jnsh779q7j6lld2k1i6hbogt3